365 related articles for article (PubMed ID: 11345205)
1. Long-term outcome of treatment with protocols AL841, AL851, and ALHR88 in children with acute lymphoblastic leukemia: results obtained by the Kyushu-Yamaguchi Children's Cancer Study Group.
Matsuzaki A; Ishii E; Nagatoshi Y; Eguchi H; Koga H; Yanai F; Inada H; Nibu K; Tamai Y; Akiyoshi K; Nakayama H; Hara T; Take H; Miyazaki S; Okamura J
Int J Hematol; 2001 Apr; 73(3):369-77. PubMed ID: 11345205
[TBL] [Abstract][Full Text] [Related]
2. Treatment of high-risk acute lymphoblastic leukemia in children using the AL851 and ALHR88 protocols: a report from the Kyushu-Yamaguchi Children's Cancer Study Group in Japan.
Matsuzaki A; Ishii E; Okamura J; Eguchi H; Yoshida N; Yanai F; Inoue T; Miyake K; Ishihara T; Tsuboi C
Med Pediatr Oncol; 1996 Jan; 26(1):10-9. PubMed ID: 7494507
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of intensified rotational combination chemotherapy for late hematologic relapse of childhood acute lymphoblastic leukemia.
Rivera GK; Hudson MM; Liu Q; Benaim E; Ribeiro RC; Crist WM; Pui CH
Blood; 1996 Aug; 88(3):831-7. PubMed ID: 8704238
[TBL] [Abstract][Full Text] [Related]
4. Neurodevelopmental outcome of infants with acute lymphoblastic leukemia: a Children's Cancer Group report.
Kaleita TA; Reaman GH; MacLean WE; Sather HN; Whitt JK
Cancer; 1999 Apr; 85(8):1859-65. PubMed ID: 10223582
[TBL] [Abstract][Full Text] [Related]
5. [The programmed therapy of acute lymphoblastic leukemia in adults].
Isaev VG; Savchenko VG; Kucher RA; Abakumov EM; Parovichnikova EN
Ter Arkh; 1992; 64(8):82-7. PubMed ID: 1440405
[No Abstract] [Full Text] [Related]
6. Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials. UK Medical Research Council's Working Party on Childhood Leukaemia.
Hann I; Vora A; Richards S; Hill F; Gibson B; Lilleyman J; Kinsey S; Mitchell C; Eden OB
Leukemia; 2000 Mar; 14(3):356-63. PubMed ID: 10720126
[TBL] [Abstract][Full Text] [Related]
7. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.
Marshall GM; Dalla Pozza L; Sutton R; Ng A; de Groot-Kruseman HA; van der Velden VH; Venn NC; van den Berg H; de Bont ES; Maarten Egeler R; Hoogerbrugge PM; Kaspers GJ; Bierings MB; van der Schoot E; van Dongen J; Law T; Cross S; Mueller H; de Haas V; Haber M; Révész T; Alvaro F; Suppiah R; Norris MD; Pieters R
Leukemia; 2013 Jul; 27(7):1497-503. PubMed ID: 23407458
[TBL] [Abstract][Full Text] [Related]
8. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncology Group Study (E3486).
Wiernik PH; Cassileth PA; Leong T; Hoagland HC; Bennett JM; Paietta E; Oken MM;
Leuk Lymphoma; 2003 Sep; 44(9):1515-21. PubMed ID: 14565653
[TBL] [Abstract][Full Text] [Related]
10. Treating childhood acute lymphoblastic leukemia without cranial irradiation.
Pui CH; Campana D; Pei D; Bowman WP; Sandlund JT; Kaste SC; Ribeiro RC; Rubnitz JE; Raimondi SC; Onciu M; Coustan-Smith E; Kun LE; Jeha S; Cheng C; Howard SC; Simmons V; Bayles A; Metzger ML; Boyett JM; Leung W; Handgretinger R; Downing JR; Evans WE; Relling MV
N Engl J Med; 2009 Jun; 360(26):2730-41. PubMed ID: 19553647
[TBL] [Abstract][Full Text] [Related]
11. Parotid acinar cell carcinoma in a long-term survivor of childhood acute lymphoblastic leukemia.
Cheuk DK; Shek TW; Chan GC; Lau YL; Ha SY; Chiang AK
Pediatr Blood Cancer; 2008 Mar; 50(3):636-9. PubMed ID: 16865683
[TBL] [Abstract][Full Text] [Related]
12. [Clinical trial of protocol-AL851 for children with high-risk acute lymphoblastic leukemia. Kyushu Yamaguchi Children's Cancer Study Group (KYCCSG)].
Matsuzaki A; Ishii E; Ueda K; Yanai F; Nibu K; Take H; Koga H; Miyazaki S; Inoue T; Miyake K
Rinsho Ketsueki; 1994 Sep; 35(9):862-70. PubMed ID: 7967055
[TBL] [Abstract][Full Text] [Related]
13. Long-term Results of the Risk-adapted Treatment for Childhood B-Cell Acute Lymphoblastic Leukemia: Report From the Japan Association of Childhood Leukemia Study ALL-97 Trial.
Horibe K; Yumura-Yagi K; Kudoh T; Nishimura S; Oda M; Yoshida M; Komada Y; Hara J; Tawa A; Usami I; Tanizawa A; Kato K; Kobayashi R; Matsuo K; Hori H;
J Pediatr Hematol Oncol; 2017 Mar; 39(2):81-89. PubMed ID: 28169879
[TBL] [Abstract][Full Text] [Related]
14. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
Tzortzatou-Stathopoulou F; Papadopoulou AL; Moschovi M; Botsonis A; Tsangaris GT
J Pediatr Hematol Oncol; 2001 Dec; 23(9):591-7. PubMed ID: 11902303
[TBL] [Abstract][Full Text] [Related]
15. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
Hongo T; Yajima S; Sakurai M; Horikoshi Y; Hanada R
Blood; 1997 Apr; 89(8):2959-65. PubMed ID: 9108416
[TBL] [Abstract][Full Text] [Related]
16. Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica.
Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi A; Miniero R; Di Tullio MT; Lo Nigro L; Pession A; Rondelli R; Messina C; Santoro N; Mori PG; De Rossi G; Tamaro P; Silvestri D; Biondi A; Basso G; Masera G
Haematologica; 1998 Sep; 83(9):791-9. PubMed ID: 9825576
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up results of adult patients with acute lymphocytic leukemia or lymphoblastic lymphoma treated with short-term, alternating non-cross-resistant chemotherapy: Japan Clinical Oncology Group Study 8702. Lymphoma Study Group.
Kobayashi T; Tobinai K; Shimoyama M; Mikuni C; Konda S; Kozuru M; Araki K; Sai T; Fukuhara S; Matsumoto M; Aoki I; Deura K; Oyama A; Hotta T; Abe T; Toki H; Nagai M; Fukuda H; Niimi M; Yamaguchi N; Tajima K; Shirakawa S
Jpn J Clin Oncol; 1999 Jul; 29(7):340-8. PubMed ID: 10470659
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes of modified BFM-95 regimen in adults with newly diagnosed standard-risk acute lymphoblastic leukemia: a retrospective single-center study.
Li C; Cai X; Chen X; Liang Y; Xia Z; Wang H
Int J Hematol; 2019 Oct; 110(4):458-465. PubMed ID: 31321731
[TBL] [Abstract][Full Text] [Related]
19. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Sancho JM; Ribera JM; Xicoy B; Morgades M; Oriol A; Tormo M; del Potro E; Debén G; Abella E; Bethencourt C; Ortín X; Brunet S; Ortega-Rivas F; Novo A; López R; Hernández-Rivas JM; Sanz MA; Feliu E;
Eur J Haematol; 2007 Feb; 78(2):102-10. PubMed ID: 17087744
[TBL] [Abstract][Full Text] [Related]
20. Favorable outcome for children and adolescents with T-cell lymphoblastic lymphoma with an intensive ALL-type therapy without local radiotherapy.
Grenzebach J; Schrappe M; Ludwig WD; Parwaresch R; Zimmermann M; Gadner H; Riehm H; Reiter A;
Ann Hematol; 2001; 80 Suppl 3():B73-6. PubMed ID: 11757713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
